India's Contract Research, Development and Manufacturing Organisation (CRDMO) sector is poised for accelerated growth, supported by surging global pharma outsourcing, rising demand for complex modalities, and geopolitical supply-chain realignment, according to a report by Kotak Mutual Fund.
The growth of the Indian pharmaceuticals market (IPM) continues to remain muted in November, staying in single-digit territory for the past 32 months, Nomura said in its latest report.
New Delhi [India], November 21: The Organisation of Pharmaceutical Producers of India (OPPI) organized its flagship Annual Summit today at Shangri-La Eros, New Delhi. The summit brought together a distinguished assembly of key Government officials, regulators, industry leaders, member organi
The Indian pharmaceutical sector supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medicines in the UK. According to a government release, drug and pharmaceutical exports increased by 6.94 per cent from USD 2.35
Chennai (Tamil Nadu) [India], September 3: FDC Ltd, one of India's top 25 pharmaceutical companies, has significantly strengthened its field operations through a six-year-long partnership with SANeForce, a leading provider of Pharma SFA software. With more than 5,000 field forces using the S
Indian pharma and healthcare sector will witness steady revenue growth in the first quarter of the Financial Year 2026 (Q1FY26E), but concerns loom as EBITDA margins are expected to decline amid rising input costs and pricing pressures, according to a report by HDFC Securities.
In recent order announced by the US President Donald Trump which aims to slash prescriptive drug prices in the United States to be lowered by up to 80 per cent, is likely to create ripple effect in the Global pharmaceutical landscape, raising alarms about potential repercussions for India's
Pharma companies in India are expected to report healthy earnings growth in the just-concluded October-December quarter, averaging 19.4 per cent, as per a report by brokerage firm Motilal Oswal.
Vice President of Shanghai Pharmaceuticals Li Dongming said on Tuesday that he hopes there will be more investment from Indian pharma companies in China and there will be opportunities to co-develop products for markets in other countries.